Birchview Capital’s Gossamer Bio GOSS Stock Holding History

Birchview Capital’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.97K	Sell	18,176 -120,000	-87%	-$189K	﹤0.01%	73
2025 Q4	$428K	Hold	138,176	–	–	0.25%	54
2025 Q3	$363K	Hold	138,176	–	–	0.27%	56
2025 Q2	$170K	Hold	138,176	–	–	0.17%	60
2025 Q1	$152K	Hold	138,176	–	–	0.13%	56
2024 Q4	$125K	Hold	138,176	–	–	0.1%	59
2024 Q3	$136K	Hold	138,176	–	–	0.12%	50
2024 Q2	$124K	Hold	138,176	–	–	0.12%	52
2024 Q1	$163K	Hold	138,176	–	–	0.13%	52
2023 Q4	$126K	Sell	138,176 -70,912	-34%	-$52.4K	0.1%	53
2023 Q3	$174K	Buy	209,088 +110,000	+111%	+$127K	0.15%	46
2023 Q2	$119K	Hold	99,088	–	–	0.09%	51
2023 Q1	$125K	Hold	99,088	–	–	0.1%	49
2022 Q4	$215K	Sell	99,088 -60,000	-38%	-$494K	0.15%	50
2022 Q3	$1.91M	Hold	159,088	–	–	1.34%	18
2022 Q2	$1.33M	Buy	159,088 +30,000	+23%	+$232K	0.97%	18
2022 Q1	$1.12M	Buy	129,088 +29,088	+29%	+$281K	0.81%	23
2021 Q4	$1.13M	Buy	100,000 +60,000	+150%	+$713K	0.73%	28
2021 Q3	$503K	Buy	+40,000	New	+$368K	0.34%	42
2020 Q1	–	Sell	-30,000	Closed	-$469K	–	47
2019 Q4	$469K	Buy	+30,000	New	+$604K	0.34%	35

Other funds holding GOSS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Birchview Capital's GOSS Position: Q1 2026 in Review

Birchview Capital reduced its Gossamer Bio (GOSS) stake by 87% in Q1 2026, selling an estimated $189K and leaving 18,176 shares worth $5.97K. The position accounts for ﹤0.01% of the portfolio, ranked #73.

Birchview Capital first reported a position in GOSS in Q4 2019 and has held it in 20 quarters since. The position peaked at $1.91M in Q3 2022. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

Birchview Capital held 18,176 shares of Gossamer Bio worth $5.97K as of Q1 2026.
Birchview Capital sold 120,000 Gossamer Bio shares in Q1 2026, an estimated $189K.
Gossamer Bio made up ﹤0.01% of Birchview Capital's portfolio in Q1 2026, its #73 holding.
Birchview Capital first reported a position in Gossamer Bio in Q4 2019 and has held it in 20 quarters since.
Birchview Capital's Gossamer Bio position peaked at $1.91M in Q3 2022.
184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.